Small-molecule inhibitors of the PI3K signaling network

Papers of special note have been highlighted as: ▪ of interest

Bibliography

• 1  Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet.7(8),606–619 (2006).
  Medline CASGoogle Scholar
• 2  Martin TF. Phosphoinositide lipids as signaling molecules: common themes for signal transduction, cytoskeletal regulation, and membrane trafficking. Annu. Rev. Cell Dev. Biol.14,231–264 (1998).
  Medline CASGoogle Scholar
• 3  Toker A. Phosphoinositides and signal transduction. Cell. Mol. Life Sci.59(5),761–779 (2002).
  Medline CASGoogle Scholar
• 4  Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu. Rev. Biochem.67,481–507 (1998).
  Medline CASGoogle Scholar
• 5  Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol.11(5),329–341 (2010).
  Medline CASGoogle Scholar
• 6  Stephens LR, Jackson TR, Hawkins PT. Agonist-stimulated synthesis of phosphatidylinositol(3,4,5)-trisphosphate: a new intracellular signalling system? Biochim. Biophys. Acta1179(1),27–75 (1993).
  Medline CASGoogle Scholar
• 7  Rameh LE, Cantley LC. The role of phosphoinositide 3-kinase lipid products in cell function. J. Biol. Chem.274(13),8347–8350 (1999).
  Medline CASGoogle Scholar
• 8  Kutateladze TG. Translation of the phosphoinositide code by PI effectors. Nat. Chem. Biol.6(7),507–513 (2010).
  Medline CASGoogle Scholar
• 9  Brognard J, Newton AC. PHLiPPing the switch on Akt and protein kinase C signaling. Trends Endocrinol. Metab.19(6),223–230 (2008).
  Medline CASGoogle Scholar
• 10  Arroyo JD, Hahn WC. Involvement of PP2A in viral and cellular transformation. Oncogene24(52),7746–7755 (2005).
  Medline CASGoogle Scholar
• 11  Brazil DP, Yang ZZ, Hemmings BA. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem. Sci.29(5),233–242 (2004).
  Medline CASGoogle Scholar
• 12  Mora A, Komander D, van Aalten DMF, Alessi DR. PDK1, the master regulator of AGC kinase signal transduction. Semin. Cell Dev. Biol.15(2),161–170 (2004).
  Medline CASGoogle Scholar
• 13  Currie RA, Walker KS, Gray A et al. Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1. Biochem. J.337(Pt. 3),575–583 (1999).
  Medline CASGoogle Scholar
• 14  Alessi DR, James SR, Downes CP et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα. Curr. Biol.7(4),261–269 (1997).
  Medline CASGoogle Scholar
• 15  Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science307(5712),1098–1101 (2005).
  Medline CASGoogle Scholar
• 16  Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu. Rev. Biochem.68,965–1014 (1999).
  Medline CASGoogle Scholar
• 17  Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell129(7),1261–1274 (2007).▪ Comprehensive review of the Akt signaling pathway.
  Medline CASGoogle Scholar
• 18  Datta SR, Dudek H, Tao X et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell91(2),231–241 (1997).
  Medline CASGoogle Scholar
• 19  Van Der Heide LP, Hoekman MF, Smidt MP. The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem. J.380(Pt. 2),297–309 (2004).
  Medline CASGoogle Scholar
• 20  Marine JC, Lozano G. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ.17(1),93–102 (2010).
  Medline CASGoogle Scholar
• 21  Nair VD, Olanow CW. Differential modulation of Akt/glycogen synthase kinase-3β pathway regulates apoptotic and cytoprotective signaling responses. J. Biol. Chem.283(22),15469–15478 (2008).
  Medline CASGoogle Scholar
• 22  Foster KG, Fingar DC. Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J. Biol. Chem.285(19),14071–14077 (2010).
  Medline CASGoogle Scholar
• 23  Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle2(4),339–345 (2003).
  Medline CASGoogle Scholar
• 24  Danial NN, Walensky LD, Zhang C-Y et al. Dual role of proapoptotic BAD in insulin secretion and β cell survival. Nat. Med.14(2),144–153 (2008).
  Medline CASGoogle Scholar
• 25  Matheny RW Jr, Adamo ML. Current perspectives on Akt Akt-ivation and Akt-ions. Exp. Biol. Med. (Maywood)234(11),1264–1270 (2009).
  Medline CASGoogle Scholar
• 26  Toker A, Yoeli-Lerner M. Akt signaling and cancer: surviving but not moving on. Cancer Res.66(8),3963–3966 (2006).
  Medline CASGoogle Scholar
• 27  Chin YR, Toker A. The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration. Mol. Cell38(3),333–344 (2010).
  Medline CASGoogle Scholar
• 28  Iliopoulos D, Polytarchou C, Hatziapostolou M et al. MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci. Signal.2(92),ra62 (2009).
  MedlineGoogle Scholar
• 29  Maroulakou IG, Oemler W, Naber SP, Tsichlis PN. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res.67(1),167–177 (2007).
  Medline CASGoogle Scholar
• 30  Park WS, Heo WD, Whalen JH et al. Comprehensive identification of PIP₃-regulated PH domains from C. elegans to H. sapiens by model prediction and live imaging. Mol. Cell30(3),381–392 (2008).▪ Describes the development of a model system that was used to predict which pleckstrin homology (PH) domain-containing proteins are regulated by PIP3.
  Medline CASGoogle Scholar
• 31  Vasudevan KM, Barbie DA, Davies MA et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell16(1),21–32 (2009).▪ Demonstrates that phosphoinositide 3-kinase may promote cancer through 
either AKT-dependent or 
AKT-independent mechanisms.
  Medline CASGoogle Scholar
• 32  Dawes AT, Edelstein-Keshet L. Phosphoinositides and Rho proteins spatially regulate actin polymerization to initiate and maintain directed movement in a one-dimensional model of a motile cell. Biophys. J.92(3),744–768 (2007).
  Medline CASGoogle Scholar
• 33  Kölsch V, Charest PG, Firtel RA. The regulation of cell motility and chemotaxis by phospholipid signaling. J. Cell Sci.121(5),551–559 (2008).
  Medline CASGoogle Scholar
• 34  Takenawa T, Itoh T. Phosphoinositides, key molecules for regulation of actin cytoskeletal organization and membrane traffic from the plasma membrane. Biochim. Biophys. Acta1533(3),190–206 (2001).
  Medline CASGoogle Scholar
• 35  Hirsch E, Ciraolo E, Ghigo A, Costa C. Taming the PI3K team to hold inflammation and cancer at bay. Pharmacol. Ther.118(2),192–205 (2008).
  Medline CASGoogle Scholar
• 36  Oudit GY, Penninger JM. Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc. Res.82(2),250–260 (2009).
  Medline CASGoogle Scholar
• 37  Manning BD. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J. Cell Biol.167(3),399–403 (2004).
  Medline CASGoogle Scholar
• 38  Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov.8(8),627–644 (2009).▪ Thorough review of the role of the phosphoinositide 3-kinase pathway in cancer and the development of therapeutic inhibitors of this pathway.
  Medline CASGoogle Scholar
• 39  Mandelker D, Gabelli SB, Schmidt-Kittler O et al. A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane. Proc. Natl Acad. Sci. USA106(40),16996–17001 (2009).
  Medline CASGoogle Scholar
• 40  Carpten JD, Faber AL, Horn C et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature448(7152),439–444 (2007).
  Medline CASGoogle Scholar
• 41  Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim. Biophys. Acta1784(1),159–185 (2008).
  Medline CASGoogle Scholar
• 42  Cleary JM, Shapiro GI. Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer. Curr. Oncol. Rep.12(2),87–94 (2010).
  Medline CASGoogle Scholar
• 43  Ihle NT, Williams R, Chow S et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol. Cancer Ther.3(7),763–772 (2004).
  Medline CASGoogle Scholar
• 44  Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem.269(7),5241–5248 (1994).
  Medline CASGoogle Scholar
• 45  Garlich JR, De P, Dey N et al. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res.68(1),206–215 (2008).
  Medline CASGoogle Scholar
• 46  Calvo E, Edelman G, Baselga J et al. A Phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL147, a novel PI3K inhibitor administered orally to patients with advanced solid tumors. Ejc Suppl.6(12),69–69 (2008).
  Google Scholar
• 47  Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer9(8),550–562 (2009).
  Medline CASGoogle Scholar
• 48  Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell8(3),179–183 (2005).
  Medline CASGoogle Scholar
• 49  O’Reilly KE, Rojo F, She QB et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res.66(3),1500–1508 (2006).
  MedlineGoogle Scholar
• 50  Raynaud FI, Eccles S, Clarke PA et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res.67(12),5840–5850 (2007).
  Medline CASGoogle Scholar
• 51  Workman P, Clarke PA, Raynaud FI, Van Montfort RLM. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res.70(6),2146–2157 (2010).
  Medline CASGoogle Scholar
• 52  Fan QW, Knight ZA, Goldenberg DD et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell9(5),341–349 (2006).
  Medline CASGoogle Scholar
• 53  Folkes AJ, Ahmadi K, Alderton WK et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem.51(18),5522–5532 (2008).
  Medline CASGoogle Scholar
• 54  Wagner AJ, Von Hoff DH, LoRusso PM et al. A first-in-human Phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. J. Clin. Oncol.27(15),3501 (2009).
  Google Scholar
• 55  Maira SM, Stauffer F, Brueggen J et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther.7(7),1851–1863 (2008).
  Medline CASGoogle Scholar
• 56  Eichhorn PJ, Gili M, Scaltriti M et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res.68(22),9221–9230 (2008).
  Medline CASGoogle Scholar
• 57  Serra V, Markman B, Scaltriti M et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res.68(19),8022–8030 (2008).
  Medline CASGoogle Scholar
• 58  Knight SD, Adams ND, Burgess JL et al. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. Acs Med. Chem. Lett.1(1),39–43 (2010).
  Medline CASGoogle Scholar
• 59  Venkatesan AM, Dehnhardt CM, Delos Santos E et al. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5´-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J. Med. Chem.53(6),2636–2645 (2010).
  Medline CASGoogle Scholar
• 60  Cheng HM, Bagrodia S, Bailey S et al. Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design. MedChemComm1(2),139–144 (2010).
  CASGoogle Scholar
• 61  Bi L, Okabe I, Bernard DJ, Nussbaum RL. Early embryonic lethality in mice deficient in the p110β catalytic subunit of PI 3-kinase. Mamm. Genome13(3),169–172 (2002).
  Medline CASGoogle Scholar
• 62  Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110α subunit of phosphoinositide 3-kinase. J. Biol. Chem.274(16),10963–10968 (1999).
  Medline CASGoogle Scholar
• 63  Knight ZA, Gonzalez B, Feldman ME et al. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell125(4),733–747 (2006).
  Medline CASGoogle Scholar
• 64  Sadhu C, Masinovsky B, Dick K, Sowell CG, Staunton DE. Essential role of phosphoinositide 3-kinase δ in neutrophil directional movement. J. Immunol.170(5),2647–2654 (2003).
  Medline CASGoogle Scholar
• 65  Billottet C, Grandage VL, Gale RE et al. A selective inhibitor of the p110δ isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene25(50),6648–6659 (2006).
  Medline CASGoogle Scholar
• 66  Flinn W, Byrd J, Furman R et al. Preliminary evidence of clinical activity in a Phase I study of Cal-101, a potent selective inhibitor of the P110δ isoform of phosphatidylinositol 3-kinase, in patient with B-cell malignancies. Haematol-Hematol. J.94,303–303 (2009).
  Google Scholar
• 67  Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene27(41),5511–5526 (2008).
  Medline CASGoogle Scholar
• 68  Crowell JA, Steele VE, Fay JR. Targeting the AKT protein kinase for cancer chemoprevention. Mol. Cancer Ther.6(8),2139–2148 (2007).
  Medline CASGoogle Scholar
• 69  LoPiccolo J, Granville CA, Gills JJ, Dennis PA. Targeting Akt in cancer therapy. Anticancer Drugs18(8),861–874 (2007).
  Medline CASGoogle Scholar
• 70  Rhodes N, Heerding DA, Duckett DR et al. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res.68(7),2366–2374 (2008).
  Medline CASGoogle Scholar
• 71  Lindsley CW, Zhao Z, Leister WH et al. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett.15(3),761–764 (2005).
  Medline CASGoogle Scholar
• 72  Wu WI, Voegtli WC, Sturgis HL, Dizon FP, Vigers GPA, Brandhuber BJ. Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition. PLoS One5(9),e12913 (2010).
  MedlineGoogle Scholar
• 73  Hirai H, Sootome H, Nakatsuru Y et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol. Cancer Ther.9(7),1956–1967 (2010).
  Medline CASGoogle Scholar
• 74  Voliva CF, Pecchi S, Burger M et al. Biological characterization of NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials. Presented at: The 101st American Association for Cancer Research Congress, WA, DC, USA, 20 April 2010.
  Google Scholar
• 75  Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov.5(8),671–688 (2006).
  Medline CASGoogle Scholar
• 76  Atkins MB, Hidalgo M, Stadler WM et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol.22(5),909–918 (2004).
  Medline CASGoogle Scholar
• 77  Feldman ME, Apsel B, Uotila A et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol.7(2),e38 (2009).
  MedlineGoogle Scholar
• 78  Thoreen CC, Kang SA, Chang JW et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem.284(12),8023–8032 (2009).
  Medline CASGoogle Scholar
• 79  Liu Q, Chang JW, Wang J et al. Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J. Med. Chem.53(19),7146–7155 (2010).
  Medline CASGoogle Scholar
• 80  Chresta CM, Davies BR, Hickson I et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer. Res.70(1),288–298 (2010).
  Medline CASGoogle Scholar
• 81  Carayol N, Vakana E, Sassano A et al. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc. Natl Acad. Sci. USA107(28),12469–12474 (2010).
  Medline CASGoogle Scholar
• 82  Peifer C, Alessi DR. Small-molecule inhibitors of PDK1. ChemMedChem3(12),1810–1838 (2008).
  Medline CASGoogle Scholar
• 83  Stockman BJ, Kothe M, Kohls D et al. Identification of allosteric PIF-pocket ligands for PDK1 using NMR-based fragment screening and ¹H-¹⁵N TROSY experiments. Chem. Biol. Drug Des.73(2),179–188 (2009).
  Medline CASGoogle Scholar
• 84  Bobkova EV, Weber MJ, Xu Z et al. Discovery of PDK1 kinase inhibitors with a novel mechanism of action by ultrahigh throughput screening. J. Biol. Chem.285(24),18838–18846 (2010).
  Medline CASGoogle Scholar
• 85  Lemmon MA, Ferguson KM. Molecular determinants in pleckstrin homology domains that allow specific recognition of phosphoinositides. Biochem. Soc. Trans.29(Pt. 4),377–384 (2001).
  Medline CASGoogle Scholar
• 86  Haslam RJ, Koide HB, Hemmings BA. Pleckstrin domain homology. Nature363(6427),309–310 (1993).
  Medline CASGoogle Scholar
• 87  Mayer BJ, Ren R, Clark KL, Baltimore D. A putative modular domain present in diverse signaling proteins. Cell73(4),629–630 (1993).
  Medline CASGoogle Scholar
• 88  DiNitto JP, Lambright DG. Membrane and juxtamembrane targeting by PH and PTB domains. Biochim. Biophys. Acta1761(8),850–867 (2006).▪ Provides a helpful overview of PH domain structures.
  Medline CASGoogle Scholar
• 89  Lemmon MA. Pleckstrin homology domains: not just for phosphoinositides. Biochem. Soc. Trans.32(Pt. 5),707–711 (2004).
  Medline CASGoogle Scholar
• 90  Harlan JE, Hajduk PJ, Yoon HS, Fesik SW. Pleckstrin homology domains bind to phosphatidylinositol-4,5-bisphosphate. Nature371(6493),168–170 (1994).
  Medline CASGoogle Scholar
• 91  Yu JW, Mendrola JM, Audhya A et al. Genome-wide analysis of membrane targeting by S. cerevisiae pleckstrin homology domains. Mol. Cell13(5),677–688 (2004).
  Medline CASGoogle Scholar
• 92  Isakoff SJ, Cardozo T, Andreev J et al. Identification and analysis of PH domain-containing targets of phosphatidylinositol 3-kinase using a novel in vivo assay in yeast. EMBO J.17(18),5374–5387 (1998).
  Medline CASGoogle Scholar
• 93  Ferguson KM, Kavran JM, Sankaran VG et al. Structural basis for discrimination of 3-phosphoinositides by pleckstrin homology domains. Mol. Cell6(2),373–384 (2000).
  Medline CASGoogle Scholar
• 94  Kontos CD, Stauffer TP, Yang WP et al. Tyrosine 1101 of Tie2 is the major site of association of p85 and is required for activation of phosphatidylinositol 3-kinase and Akt. Mol. Cell. Biol.18(7),4131–4140 (1998).
  Medline CASGoogle Scholar
• 95  Stauffer TP, Ahn S, Meyer T. Receptor-induced transient reduction in plasma membrane PtdIns(4,5)P2 concentration monitored in living cells. Curr. Biol.8(6),343–346 (1998).
  Medline CASGoogle Scholar
• 96  Lansbergen G, Grigoriev I, Mimori-Kiyosue Y et al. CLASPs attach microtubule plus ends to the cell cortex through a complex with LL5β. Dev. Cell11(1),21–32 (2006).
  Medline CASGoogle Scholar
• 97  Takabayashi T, Xie MJ, Takeuchi S et al. LL5β directs the translocation of filamin A and SHIP2 to sites of phosphatidylinositol 3,4,5-triphosphate (PtdIns(3,4,5)P3) accumulation, and PtdIns(3,4,5)P3 localization is mutually modified by co-recruited SHIP2. J. Biol. Chem.285(21),16155–16165 (2010).
  Medline CASGoogle Scholar
• 98  Plantard L, Arjonen A, Lock JG, Nurani G, Ivaska J, Stromblad S. PtdIns(3,4,5)P₃ is a regulator of myosin-X localization and filopodia formation. J. Cell Sci.123(Pt. 20),3525–3534 (2010).
  Medline CASGoogle Scholar
• 99  Hamaguchi N, Ihara S, Ohdaira T et al. Pleckstrin-2 selectively interacts with phosphatidylinositol 3-kinase lipid products and regulates actin organization and cell spreading. Biochem. Biophys. Res. Commun.361(2),270–275 (2007).
  Medline CASGoogle Scholar
• 100  Qu X, Kawauchi-Kamata K, Miah SM, Hatani T, Yamamura H, Sada K. Tyrosine phosphorylation of adaptor protein 3BP2 induces T-cell receptor-mediated activation of transcription factor. Biochemistry44(10),3891–3898 (2005).
  Medline CASGoogle Scholar
• 101  Cullen PJ, Venkateswarlu K. Potential regulation of ADP-ribosylation factor 6 signalling by phosphatidylinositol 3,4,5-trisphosphate. Biochem. Soc. Trans.27(4),683–689 (1999).
  Medline CASGoogle Scholar
• 102  Falasca M. PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs. Curr. Pharm. Des.16(12),1410–1416 (2010).
  Medline CASGoogle Scholar
• 103  Berrie CP, Falasca M. Patterns within protein/polyphosphoinositide interactions provide specific targets for therapeutic intervention. FASEB J.14(15),2618–2622 (2000).
  Medline CASGoogle Scholar
• 104  Razzini G, Berrie CP, Vignati S et al. Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines. FASEB J.14(9),1179–1187 (2000).
  Medline CASGoogle Scholar
• 105  Piccolo E, Vignati S, Maffucci T et al. Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway. Oncogene23(9),1754–1765 (2004).
  Medline CASGoogle Scholar
• 106  Maffucci T, Piccolo E, Cumashi A et al. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects. Cancer Res.65(18),8339–8349 (2005).
  Medline CASGoogle Scholar
• 107  Falasca M, Chiozzotto D, Godage HY et al. A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate. Br. J. Cancer102(1),104–114 (2010).
  Medline CASGoogle Scholar
• 108  Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol. Cancer Ther.2(11),1093–1103 (2003).
  Medline CASGoogle Scholar
• 109  Gills JJ, Dennis PA. Perifosine: update on a novel Akt inhibitor. Curr. Oncol. Rep.11(2),102–110 (2009).
  Medline CASGoogle Scholar
• 110  Meuillet EJ, Mahadevan D, Vankayalapati H et al. Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues. Mol. Cancer Ther.2(4),389–399 (2003).
  Medline CASGoogle Scholar
• 111  Kozikowski AP, Sun H, Brognard J, Dennis PA. Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. J. Am. Chem. Soc.125(5),1144–1145 (2003).
  Medline CASGoogle Scholar
• 112  Castillo SS, Brognard J, Petukhov PA et al. Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. Cancer Res.64(8),2782–2792 (2004).
  Medline CASGoogle Scholar
• 113  Meuillet EJ, Ihle N, Baker AF et al. In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. Oncol. Res.14(10),513–527 (2004).
  Medline CASGoogle Scholar
• 114  Thomas CC, Deak M, Alessi DR, van Aalten DM. High-resolution structure of the pleckstrin homology domain of protein kinase B/Akt bound to phosphatidylinositol (3,4,5)-trisphosphate. Curr. Biol.12(14),1256–1262 (2002).
  Medline CASGoogle Scholar
• 115  Mahadevan D, Powis G, Mash EA et al. Discovery of a novel class of AKT pleckstrin homology domain inhibitors. Mol. Cancer Ther.7(9),2621–2632 (2008).
  Medline CASGoogle Scholar
• 116  Moses SA, Ali MA, Zuohe S et al. In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT. Cancer Res.69(12),5073–5081 (2009).
  Medline CASGoogle Scholar
• 117  Meuillet EJ, Zuohe S, Lemos R et al. Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol. Cancer Ther.9(3),706–717 (2010).
  Medline CASGoogle Scholar
• 118  Kim D, Sun M, He L et al. A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation. J. Biol. Chem.285(11),8383–8394 (2010).
  Medline CASGoogle Scholar
• 119  Berndt N, Yang H, Trinczek B et al. The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane. Cell Death Differ.17(11),1795–1804 (2010).▪ Characterizes a phosphatidylinositol-(3,4,5)-trisphosphate/PH domain inhibitor that is currently in clinical trials.
  Medline CASGoogle Scholar
• 120  Garrett CR, Coppola D, Wenham RM et al. Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest. New Drugs DOI: 10.1007/s10637-010-9479-2 (2010). (Epub ahead of print).
  Google Scholar
• 121  Miao B, Skidan I, Yang J et al. Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP₃) binding to pleckstrin homology domains. Proc. Natl Acad. Sci. USA107(46),20126–20131 (2010).
  Medline CASGoogle Scholar